Acelity L.P. Inc. 10-K Annual Report March 2016


•	Revenue for the fourth quarter of 2015 of $483.8 million, grew 0.2% as reported on a GAAP basis from the prior-year period and grew 3.4% on a constant currency basis, bringing revenue for the full year of 2015 to $1.867 billion, which was comparable to the prior year as reported on a GAAP basis and up 4.0% on a constant currency basis


•	Revenue from Advanced Wound Therapeutics ("AWT") decreased 1.3% as reported on a GAAP basis and grew 2.5% on a constant currency basis, led by solid volume growth in advanced devices compared to the prior-year period


•	Revenue from Regenerative Medicine ("RM") grew 6.9% as reported on a GAAP basis and grew 8.4% on a constant currency basis, led by double-digit increases in revenue related to breast reconstruction procedures in the U.S.


•	Loss from continuing operations was $15.5 million, as reported on a GAAP basis, compared to $30.9 million for the prior-year period


•	Adjusted EBITDA from continuing operations¹ of $183.5 million, declined 7.5% as reported from the prior-year period and was down 5.3% on a constant currency basis, achieving an Adjusted EBITDA margin of 37.9%

Operational Highlights


•	Closed the acquisition of the SNaP® business from Spiracur, Inc., expanding our offering in disposable, portable, mechanical negative pressure wound therapy ("NPWT") technology, allowing Acelity’s sales and service channels to support the expansion of the SNaP® Therapy System to patients and their care teams around the world who need access to NPWT devices


•	Returned the Regenerative Medicine segment to growth for the full year with two consecutive quarters of strong growth led by revenue from breast reconstruction procedures and international sales

Joe Woody, President and Chief Executive Officer, commented, “Our strong fourth quarter performance reflects the realization of strategic investments we’ve made in our business and employees to drive sustainable, long-term growth. With five consecutive quarters of organic revenue growth, 2015 marks a pivotal year for Acelity as we continue to execute our strategy.

“We delivered a solid quarter in both Advanced Wound Therapeutics and Regenerative Medicine, led by continued volume increases in advanced devices as well as double-digit growth in revenue from breast reconstruction procedures. Sales of our expansion products, led by Prevena™ and Revolve™, accelerated in the fourth quarter and continue to diversify our growth profile.

“We continue to provide value to our customers through focused innovation and an enhanced portfolio of offerings across our business. The solid momentum we generated in 2015 supports our confidence in our ability to sustain long-term growth.”

The following information was filed by Acelity L.P. Inc. on Tuesday, January 26, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1557939/000155793916000077/a201510k.htm

View differences made from one year to another to evaluate Acelity L.P. Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Acelity L.P. Inc..

Continue

Assess how Acelity L.P. Inc.'s management team is paid from their Annual Proxy

Acelity L.P. Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Acelity L.P. Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.4: Form Of Executive Equity Incentive Plan International Piu Award Agreement

Exhibit 10.5: Form Of Executive Equity Incentive Plan Standard Piu Award Agreement July 2015

Exhibit 10.6: Form Of Executive Equity Incentive Plan International Piu Award Agmt July 2015

Exhibit 10.19: Letter Of Understanding - Piccinini

Exhibit 10.20: Offer Letter - Agarwal

Exhibit 10.21: Retention Agreement - Agarwal

Exhibit 10.22: Offer Letter - Kayata

Exhibit 10.23: Retention Agreement - Kayata

Exhibit 10.35: Services Agreement - Kci And Apax

Exhibit 10.36: Services Agreement - Kci And Cppib

Exhibit 10.37: Services Agreement - Kci And Datura

Exhibit 10.38: Services Agreement - Lifecell And Apax

Exhibit 10.39: Services Agreement - Lifecell And Cppib

Exhibit 10.40: Services Agreement - Lifecell And Datura

Exhibit 10.41: Services Agreement - Kci And Chiron Topco

Exhibit 10.42: Services Agreement - Chiron Topco And Apax

Exhibit 10.43: Services Agreement - Chiron Topco And Cppib

Exhibit 10.44: Services Agreement - Chiron Topco And Datura

Exhibit 10.45: Services Agreement - Lifecell And Chiron Holdings

Exhibit 10.46: Services Agreement - Chiron Holdings And Apax

Exhibit 10.47: Services Agreement - Chiron Holdings And Cppib

Exhibit 10.48: Services Agreement - Chiron Holdings And Datura

Exhibit 21.1: Listing Of Subsidiaries

Exhibit 31.1: Ceo Certification

Exhibit 31.2: Cfo Certification

Exhibit 32.1: Ceo Certification

Exhibit 32.2: Cfo Certification

CIK: 1557939
Form Type: 10-K Annual Report
Accession Number: 0001557939-16-000077
Submitted to the SEC: Fri Mar 04 2016 7:11:18 PM EST
Accepted by the SEC: Mon Mar 07 2016
Period: Thursday, December 31, 2015
Industry: Surgical And Medical Instruments And Apparatus